Holen Sie sich die Stockscreener-App
14.41
8.12%
1.11
Schlusskurs vom Vortag:
$13.30
Offen:
$13.93
24-Stunden-Volumen:
105.24K
Relative Volume:
0.53
Marktkapitalisierung:
$1.15B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+17.01%
1M Leistung:
+14.76%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$13.44
$14.50
1-Wochen-Bereich:
$10.49
$14.50
52-Wochen-Spanne:
$8.70
$14.87
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Company Profile
Firmenname
Bridgebio Oncology Therapeutics Inc
Sektor
Branche
Telefon
857 702 0377
Adresse
256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO
Vergleichen Sie BBOT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBOT
Bridgebio Oncology Therapeutics Inc
|
14.38 | 1.06B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.17 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.41 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.74 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
811.40 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.73 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-05 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-09-17 | Eingeleitet | Leerink Partners | Outperform |
| 2025-09-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-08-15 | Eingeleitet | Piper Sandler | Overweight |
Bridgebio Oncology Therapeutics Inc Aktie (BBOT) Neueste Nachrichten
Raymond James Initiates BridgeBio Oncology Therapeutics at Outperform With $24 Price Target - MarketScreener
BridgeBio Oncology stock initiated with Outperform rating at Raymond James By Investing.com - Investing.com India
BridgeBio Oncology stock initiated with Outperform rating at Raymond James - Investing.com
BridgeBio Oncology stock price target raised to $32 from $25 at Leerink - Investing.com Canada
Oppenheimer reiterates Outperform rating on BridgeBio Oncology stock By Investing.com - Investing.com UK
BridgeBio Oncology stock maintains Overweight rating at Morgan Stanley - Investing.com
BridgeBio Oncology stock maintains Overweight rating at Morgan Stanley By Investing.com - Investing.com India
BBOT: Promising efficacy and safety for three RAS-pathway inhibitors, with key data expected in 2026 - TradingView — Track All Markets
BridgeBio Oncology reports positive data from RAS-pathway cancer trials - Investing.com
BridgeBio Oncology Therapeutics, Inc. Announces New Clinical Data for RAS and PI3Kα Programs - TradingView — Track All Markets
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs - The Manila Times
BBOT Announces New Clinical Data Advancing Its Portfolio of - GlobeNewswire
BridgeBio Oncology Therapeutics, Inc.Common Stock (NQ: BBOT - FinancialContent
BridgeBio Oncology Therapeutics, Inc.(NasdaqGM: BBOT) added to S&P Global BMI Index - marketscreener.com
BridgeBio Oncology Therapeutics Earnings Notes - Trefis
BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Assessing BridgeBio Oncology Therapeutics (BBOT) Valuation After Recent Share Price Pullback - Yahoo Finance
Wedbush Reiterates BridgeBio Oncology Therapeutics (BBOT) Outperform Recommendation - MSN
BridgeBio Oncology Therapeutics (BBOT) updates CEO option grant terms - Stock Titan
BridgeBio Oncology Therapeutics: Promising KRAS Drug DeveloperIn My View, At Least - Seeking Alpha
BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Wedbush Reiterates Outperform Rating for BBOT; Price Target Unch - GuruFocus
BridgeBio Oncology initiated with an overweight at Morgan Stanley - MSN
BridgeBio Oncology (BBOT) Stock Analysis Report | Financials & Insights - Benzinga
BridgeBio Oncology Therapeutics, Inc. Announces Late-Breaking Preclinical Data on BBO-10203, a First-In-Class RAS:PI3Ka Breaker, at the San Antonio Breast Cancer Symposium - marketscreener.com
BBOT Announces Late-Breaking Preclinical Data on BBO-10203, - GlobeNewswire
BridgeBio Oncology stock reaches all-time high at 14.87 USD By Investing.com - Investing.com Canada
BridgeBio Oncology stock reaches all-time high at 14.87 USD - Investing.com India
Morgan Stanley Initiates Coverage of BridgeBio Oncology Therapeutics (BBOT) with Overweight Recommendation - Nasdaq
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
BridgeBio Oncology: Positioned for Growth with Innovative RAS-Targeted Therapies - TipRanks
Morgan Stanley Initiates BridgeBio Oncology Therapeutics With Overweight Rating, $20 Price Target - marketscreener.com
BridgeBio Oncology initiated with an Overweight at Morgan Stanley - TipRanks
Morgan Stanley initiates coverage on BridgeBio Oncology stock with Overweight rating - Investing.com India
BBOT: All three oncology programs progressed in 2025, with major data readouts and strategic decisions set for 2026 - TradingView — Track All Markets
BBOT: Wedbush Reiterates Outperform Rating with $25 Target | BBO - GuruFocus
Analysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (FULC) and Arrowhead Pharmaceuticals (ARWR) - The Globe and Mail
BBOT to Participate in Upcoming December Investor Healthcare Conferences - The Manila Times
BridgeBio Oncology Therapeutics Reports Q3 2025 Progress - TipRanks
Oppenheimer Maintains BridgeBio Oncology Therapeutics(BBOT.US) With Buy Rating, Maintains Target Price $22 - 富途牛牛
BridgeBio Oncology Therapeutics, Inc. (BBOT) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Decoding BridgeBio Oncology Therapeutics Inc (BBOT): A Strategic SWOT Insight - GuruFocus
Oppenheimer Maintains BridgeBio Oncology Therapeutics (BBOT) Outperform Recommendation - Nasdaq
BBOT Analyst Rating Update: Oppenheimer Lowers Price Target | BB - GuruFocus
Oppenheimer Adjusts BridgeBio Oncology Therapeutics Price Target to $22 From $23, Maintains Outperform Rating - MarketScreener
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress - The Manila Times
A breakup strategy that’s inspiring clinical candidates for cancer - Chemical & Engineering News
BridgeBio Oncology Therapeutics, Inc.'s (NASDAQ:BBOT) largest shareholders are individual investors who were rewarded as market cap surged US$51m last week - Yahoo Finance
Analysts Are Bullish on Top Healthcare Stocks: CytomX Therapeutics (CTMX), AbCellera Biologics (ABCL) - The Globe and Mail
BridgeBio Oncology Therapeutics Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
Finanzdaten der Bridgebio Oncology Therapeutics Inc-Aktie (BBOT)
Es liegen keine Finanzdaten für Bridgebio Oncology Therapeutics Inc (BBOT) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):